A specific protein, a so-called HPS-heat shock protein (code name: STA-9090 study) would provide for remarkable results as a bearer of other kinds of cancer with tumor hostile motes in solid tumors. The results were remarkably well, especially in lung cancer. Article update 5 July 2011
5 July 2011: last year this time, there was this message outward. Repeated again because this weeek in Amsterdam is a large international lung cancer Congress.
14 July 2010: Source Meds cape
A specific protein, a so-called HPS-heat shock protein (code name: STA-9090 study) would provide for all forms of cancer with remarkable results in solid tumors. Especially with lung cancer could this protein for an excellent effect concerns. This protein is used as accompanying other motes that can verneitigen or the tumor stops its growth. All this shows from a phase I study with half of the participating patients clinical advantage earned by this protein. Here are some paragraphs from an article from Meds cape.
The patients had advanced or metastatic solid tumors in this study for which no standard therapy existed, or that had proven refractory to other types of treatment. Each participant received STA-9090 in a 4-week cycle, consisting of a 1-hour infusion administered once a week for 3 weeks, followed by a week-long dose-free interval. Dosing began at 7 mg/m2 and escalated to 14, 23, 35, 49, 65, 86, 114, and 150 mg/m2 on subsequent cycles. Escalation continued as appropriate in increments up to 20% 259 mg/m2. Of the 53 patients, 10 had had small-cell lung cancer NSCLC, 2, and the others had tumors of the colon, prostate, pancreas, esophagus, gastrointestinal stroma, or ovary. There were also 2 cases of melanoma.
Or 42 patients evaluated for a clinical response, 1 with colon cancer achieved a partial response, and 23 others achieved stable disease, including 16 for whom the stability persisted for at least 16 weeks.
All of the patients experienced some type of adverse event, the most common being diarrhea, fatigue, abdominal pain, nausea, and anemia. The maximum tolerated dose for weekly administration was established at 216 mg/m2. Most of the events were considered mild to moderate, and none were associated with the cessation of treatment.
